Hematology & Oncology Doctors in Wenatchee, WA Accepting Medicare

7 Hematology & Oncology doctors found. Showing 1 - 7

Hanspreet Kaur, MD Internal Medicine - Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 820 N Chelan Ave, Wenatchee, WA 98801 Phone: 509-663-8711

Dr. Mitchell Garrison, MD Internal Medicine - Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 820 N Chelan Ave, Wenatchee, WA 98801 Phone: 509-663-8711

Ensi Voshtina, DO Internal Medicine - Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 820 N Chelan Ave, Wenatchee, WA 98801 Phone: 509-663-8711

David T Notter, MD Internal Medicine - Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 820 N Chelan Ave, Wenatchee, WA 98801 Phone: 509-663-8711

Dr. Amith Ahluwalia, MD Internal Medicine - Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 1201 S Miller St, Wenatchee, WA 98801 Phone: 509-662-1511

Julie C Smith, MD Internal Medicine - Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 820 N Chelan Ave, Wenatchee, WA 98801 Phone: 509-663-8711

Dr. Joseph Lowell Johnson, M.D. Internal Medicine - Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 820 N Chelan Ave, Wenatchee, WA 98801 Phone: 509-663-8711

News Archive

Many popular sunscreens do not offer enough protection

A new study has shown that a large proportion of the top selling sunscreens do not meet guidelines recommended by the American Academy of Dermatology (AAD).

Initial polytherapy effectively improves prognosis of infantile spasms

Adrenocorticotropic hormone is recommended worldwide as an initial therapy for infantile spasms. However, infantile spasms in about 50% of children cannot be fully controlled by adrenocorticotropic hormone monotherapy, seizures recur in 33% of patients who initially respond to adrenocorticotropic hormone monotherapy, and side effects are relatively common during adrenocorticotropic hormone treatment.

Extended exposure to the psoriasis medication etanercept reduces psoriasis severity without increased adverse events

Extended exposure to the psoriasis medication etanercept does not appear to cause more infections or adverse events than placebo, and improvements in several measures of disease severity were observed for up to 96 weeks of therapy, according to a study in the June issue of Archives of Dermatology.

Latest advances in AI for aging and longevity research

Insilico Medicine, one of the leaders in artificial intelligence for drug discovery, biomarker development, digital medicine, and aging research announced today the publication of its recent paper titled "Artificial Intelligence for Aging and Longevity Research: Recent Advances and Perspectives" in Ageing Research Reviews, one of the highest-impact journals in the field.

Read more Medical News

› Verified 8 days ago